Company intelligence / Profile preview

Manistee Therapeutics, Inc.

Newton, Massachusetts, United Statesmanisteetx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Manistee Therapeutics is developing a novel sublingual small molecule therapy targeting PAK4 for the treatment of migraine. Their lead program, MTX-101, is currently in Phase 2 clinical trials. The company’s approach originated from serendipitous scientific observations and aims to provide new options for migraine management based on dedicated research and clinical study[1][2][6].

Therapeutic areas: OncologyNeurology
Modalities: Small molecules[1]
Industry: Biotech

Drug pipeline

1 asset

MTX101

Beyond the preview

Go deeper on Manistee Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Manistee Therapeutics, Inc..

Explore the full profile